⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320519 | 1.00 | — | — | |
| SCHEMBL28130569 | 1.00 | — | — | |
| SCHEMBL27435090 | 0.93 | — | — | |
| SCHEMBL8718073 | 0.93 | — | — | |
| SCHEMBL27745198 | 0.85 | FFAR3 (0.30) | — | |
| SCHEMBL9755608 | 0.85 | FFAR3 (0.30) | — | |
| Lactic Acid SCHEMBL28379555 | 0.84 | TP53 (0.41) | — | |
| SCHEMBL726336 | 0.80 | FFAR3 (0.30) | — | |
| Furan SCHEMBL22470579 | 0.80 | — | — | |
| SCHEMBL10003987 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109206464-A | A kind of adenosine diphosphate core saccharide compound and preparation method thereof and bioactivity | 北京大学 | 2019-01-15 | — | — | CN | claimed |
| CN-109206464-A | A kind of adenosine diphosphate core saccharide compound and preparation method thereof and bioactivity | 北京大学 | 2019-01-15 | — | — | CN | disclosed |
| CN-103608019-B | ANTITUMOR AGENT | 学校法人近畿大学 | 2017-02-15 | — | — | CN | disclosed |
| CN-102091072-A | Nucleoside derivatives and therapeutic use thereof | REXAHN CORP | 2011-06-15 | — | — | CN | disclosed |
| CN-1980898-B | Nucleoside derivatives and their therapeutic use | REXAHN CORP | 2011-01-12 | — | — | CN | disclosed |
| EP-1732902-B1 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7405214-B2 | Nucleoside derivatives and therapeutic use thereof | REXAHN CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1980898-A | Nucleoside derivatives and their therapeutic use | REXAHN CORP (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1732902-A2 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | Rexahn Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097757-A2 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222185-A1 | Nucleoside derivatives and therapeutic uses therof | REXAHN CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
| US-4138547-A | Process for preparing 1,2,4-triazole nucleosides | ICN PHARMACEUTICALS, INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4021542-A | Derivatives of hydrazino-monosaccharides and aldohexoses which are useful as intermediates for preparing compounds or as compounds which lower the uric acid | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-03 | — | — | US | disclosed |